TSE:HLS - HLS Therapeutics Stock Price, News, & Analysis

C$15.20
-0.28 (-1.81 %)
(As of 06/25/2019 01:23 AM ET)
Today's Range
C$15.19
Now: C$15.20
C$15.50
50-Day Range
C$15.28
MA: C$16.06
C$17.73
52-Week Range
C$7.69
Now: C$15.20
C$18.03
Volume19,610 shs
Average Volume41,825 shs
Market CapitalizationC$462.41 million
P/E RatioN/A
Dividend Yield1.29%
BetaN/A
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and distributes pharmaceutical products in North American markets. It is focused on treatment products for the central nervous system and cardiovascular specialties. The company is headquartered in Toronto, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone647-495-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$61.42 million
Cash FlowC$0.46 per share
Book ValueC$5.75 per share

Profitability

Miscellaneous

Employees46
Market CapC$462.41 million
Next Earnings DateN/A
OptionableNot Optionable

Receive HLS News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.

HLS Therapeutics (TSE:HLS) Frequently Asked Questions

What is HLS Therapeutics' stock symbol?

HLS Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HLS."

How often does HLS Therapeutics pay dividends? What is the dividend yield for HLS Therapeutics?

HLS Therapeutics declared a quarterly dividend on Monday, April 29th. Investors of record on Friday, June 14th will be given a dividend of 0.05 per share on Friday, June 14th. This represents a $0.20 dividend on an annualized basis and a yield of 1.32%. The ex-dividend date of this dividend is Monday, April 29th. View HLS Therapeutics' Dividend History.

Has HLS Therapeutics been receiving favorable news coverage?

News stories about HLS stock have been trending somewhat positive this week, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. HLS Therapeutics earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the company's share price in the near future. View News Stories for HLS Therapeutics.

Who are some of HLS Therapeutics' key competitors?

Who are HLS Therapeutics' key executives?

HLS Therapeutics' management team includes the folowing people:
  • Mr. William M. Wells M.B.A., B.A., MBA, Co-Founder & Exec. Chairman (Age 58)
  • Mr. Gregory David Gubitz L.L.B., B.A., LL.B, Co-Founder, CEO & Director (Age 62)
  • Mr. Gilbert Godin, Pres & COO (Age 60)
  • Mr. Tim Hendrickson M.B.A., Chief Financial Officer (Age 48)
  • Mr. Ryan C. Lennox, Gen. Counsel & Corp. Sec. (Age 39)

How do I buy shares of HLS Therapeutics?

Shares of HLS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is HLS Therapeutics' stock price today?

One share of HLS stock can currently be purchased for approximately C$15.20.

How big of a company is HLS Therapeutics?

HLS Therapeutics has a market capitalization of C$462.41 million and generates C$61.42 million in revenue each year. HLS Therapeutics employs 46 workers across the globe.View Additional Information About HLS Therapeutics.

What is HLS Therapeutics' official website?

The official website for HLS Therapeutics is http://www.hlstherapeutics.com/.

How can I contact HLS Therapeutics?

The company can be reached via phone at 647-495-9000.


MarketBeat Community Rating for HLS Therapeutics (TSE HLS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  2 (Vote Outperform)
Underperform Votes:  2 (Vote Underperform)
Total Votes:  4
MarketBeat's community ratings are surveys of what our community members think about HLS Therapeutics and other stocks. Vote "Outperform" if you believe HLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel